Jules L Dienstag
Affiliation: Massachusetts General Hospital
- Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapyJ L Dienstag
Gastrointestinal Unit, Liver Biliary Pancreas Center, Massachusetts General Hospital, Boston, MA 02114, USA
Hepatology 30:1082-7. 1999..Our observations suggest that lamivudine can be stopped after confirmed HBeAg loss or seroconversion...
- Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patientsJules L Dienstag
Gastrointestinal Unit Medical Services, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Clin Drug Investig 27:35-49. 2007....
- Hepatitis B virus infectionJules L Dienstag
Gastrointestinal Unit (Medical Services, Massachusetts General Hospital, and Department of Medicine and Office of the Dean for Medical Education, Harvard Medical School, Boston 02114, USA
N Engl J Med 359:1486-500. 2008
- Durability of serologic response after lamivudine treatment of chronic hepatitis BJules L Dienstag
Gastrointestinal Unit Medical Services, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA
Hepatology 37:748-55. 2003..Lamivudine retreatment for reappearance of hepatitis B markers can achieve resumption of viral suppression...
- Histological outcome during long-term lamivudine therapyJules L Dienstag
Gastrointestinal Unit Medical Services, Massachusetts General Hospital, Boston, MA 02114, USA
Gastroenterology 124:105-17. 2003..One year of lamivudine for chronic hepatitis B results in histologic improvement. We aimed to assess the histological impact of longer-term treatment...
- The role of liver biopsy in chronic hepatitis CJules L Dienstag
Gastrointestinal Unit Medical Services, Massachusetts General Hospital, Boston, MA 02114, USA
Hepatology 36:S152-60. 2002..Studies to identify noninvasive laboratory markers of histological activity and stage, especially genetic predictors of accelerated disease progression, command a high priority...
- Benefits and risks of nucleoside analog therapy for hepatitis BJules L Dienstag
Gastrointestinal Unit Medical Services, Massachusetts General Hospital and the Department of Medicine and Office of the Dean for Medical Education, Harvard Medical School, Boston, MA 02114, USA
Hepatology 49:S112-21. 2009..Future studies are needed to develop drug regimens that are even more effective in achieving clinical endpoints, that are not hampered by resistance, and that are more confined in treatment duration but are more durable...
- A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis CJules L Dienstag
Gastrointestinal Unit, Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School, Boston, MA 02114, USA
Hepatology 54:396-405. 2011....
- Lamivudine as initial treatment for chronic hepatitis B in the United StatesJ L Dienstag
Liver Biliary Pancreas Center, Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School, Boston 02114, USA
N Engl J Med 341:1256-63. 1999..The primary end point with respect to efficacy was a reduction of at least 2 points in the score on the Histologic Activity Index. On this scale, scores can range from 0 (normal) to 22 (most severe abnormalities)...
- Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis BAlexander Kuo
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetss 02114, USA
Clin Gastroenterol Hepatol 2:266-72. 2004....
- A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinomaBarham K Abu Dayyeh
Gastrointestinal Unit, Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114, USA
Gastroenterology 141:141-9. 2011..We tested associations between demographic, clinical, and genetic data and development of HCC, and developed a simple predictive model in a cohort of patients with chronic hepatitis C and advanced fibrosis...
- Looking to the future: new agents for chronic hepatitis BJules L Dienstag
Massachusetts General Hospital, Harvard Medical School, Blake 4, 55 Fruit Street, Boston, MA 02114, USA
Am J Gastroenterol 101:S19-25. 2006....
- Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosisKathleen E Corey
Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts, United States of America
PLoS ONE 7:e27144. 2012..Our data do not suggest any role for vitamin D supplementation in patients with advanced chronic hepatitis C and raise the possibility that higher vitamin D levels may be associated with disease progression...
- Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workersKathleen E Corey
Harvard Medical School, Boston, MA, USA
Infect Control Hosp Epidemiol 30:1000-5. 2009..We sought to determine the safety, tolerability, and acceptance of postexposure prophylaxis with peginterferon alfa-2b in healthcare workers (HCWs) exposed to blood from HCV-infected patients...
- Rapidly progressive fibrosing cholestatic hepatitis--hepatitis C virus in HIV coinfectionPeter M Rosenberg
Department of Pathology, Massachusetts General Hospital, Boston 02114, USA
Am J Gastroenterol 97:478-83. 2002..FCH may in part explain the accelerated development of cirrhosis previously observed among coinfected patients. Clinicians should remain vigilant for FCH in the HIV/HCV population and consider antiviral treatment in this setting...
- The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohortBarham K Abu Dayyeh
Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Dig Dis Sci 56:564-8. 2011..Both animal and limited human studies have shown that RAS inhibition with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor-1 [AT-1] blockers (ARBs) has antifibrogenic properties...
- American Gastroenterological Association technical review on the management of hepatitis CJules L Dienstag
Gastrointestinal Unit (Medical Services) Massachusetts General Hospital, Department of Medicine and Office of the Dean for Medical Education, Harvard Medical School, Boston, Massachusetts, USA
Gastroenterology 130:231-64; quiz 214-7. 2006
- The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis BJules L Dienstag
J Hepatol 42:158-62. 2005
- Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) TrialLeonard B Seeff
Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Hepatology 47:605-12. 2008..Because its use among these HALT-C participants was self-motivated and uncontrolled, however, only a well-designed prospective study can determine whether silymarin provides benefit to persons with chronic hepatitis C...
- Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis CRobert J Fontana
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
Hepatology 47:789-98. 2008..The stronger correlation of the serum markers with Ishak scores suggests that serum fibrosis markers reflect the pattern of fibrosis more closely than the quantity of hepatic collagen...
- Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis CChihiro Morishima
Department of Laboratory Medicine, Virology Division, University of Washington, Seattle, WA, USA
Hepatology 48:1412-9. 2008..However, because patients with positive TMA results may achieve SVR, management decisions during therapy should not be based on a single positive TMA test result...
- Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonrespondersEugene R Schiff
Division of Hepatology, University of Miami, Jackson Medical Towers, 1500 N W 12th Avenue, Suite 1101, Miami, FL 33136, USA
J Hepatol 38:818-26. 2003..We assessed lamivudine treatment, with or without added interferon, in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had failed interferon therapy previously...
- Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis BRobert P Perrillo
Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
Hepatology 36:186-94. 2002..Asians and Caucasians had similar rates of response to lamivudine at comparable ALT levels...
- Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirinJohn G McHutchison
Division of Gastroenterology Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road N203, La Jolla, CA 92037, USA
Hepatology 35:688-93. 2002..In conclusion, measurement of hepatic HCV RNA before or after therapy reflects changes observed in serum HCV RNA, and correlates inversely with hepatic inflammation and fibrosis, but otherwise has minimal clinical use...
- Oral antivirals for chronic hepatitis BAlbert D Min
Division of Digestive Diseases, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003, USA
Clin Liver Dis 11:851-68, ix. 2007....
- Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis CMitchell L Shiffman
Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
Gastroenterology 132:103-12. 2007..However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment...
- Health-related quality of life in patients with chronic hepatitis C and advanced fibrosisHerbert L Bonkovsky
Liver Biliary Pancreatic Center and the Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA
J Hepatol 46:420-31. 2007..This study assessed HRQOL and sexual health in patients with advanced fibrosis or cirrhosis in the HALT-C Trial...
- Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohortAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48210, USA
Hepatology 42:282-92. 2005..In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC...
- Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatmentMitchell L Shiffman
Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
Gastroenterology 126:1015-23; discussion 947. 2004..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy...
- HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trialChihiro Morishima
Department of Laboratory Medicine, University of Washington, Seattle, WA 98104, USA
Hepatology 44:360-7. 2006..In patients with negative PCR results during treatment, a single positive TMA test did not exclude SVR, although persistently positive tests did...
- Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trialGregory T Everson
Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
Hepatology 44:1675-84. 2006..In conclusion, disease severity is a major independent determinant of rate of SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize antiviral therapy in these "difficult-to-cure" patients...
- Long-term safety of lamivudine treatment in patients with chronic hepatitis BAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109 0362, USA
Gastroenterology 125:1714-22. 2003..The aim of this analysis was to determine the incidence of hepatitis flares, hepatic decompensation, and liver-disease-related (LDR) serious adverse events (SAE) during long-term lamivudine treatment...
- Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis CKaren L Lindsay
Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
Clin Gastroenterol Hepatol 6:234-41. 2008..Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression...
- Hepatitis C: a bitter harvestJules L Dienstag
Ann Intern Med 144:770-1. 2006
- Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonrespondersWilliam M Lee
Control Clin Trials 25:472-92. 2004..The protocol changes enhanced enrollment while upholding the original goals of the study and its integrity...
- American Gastroenterological Association medical position statement on the management of hepatitis CJules L Dienstag
Gastroenterology 130:225-30. 2006
- Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C TrialAdrian M Di Bisceglie
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, MO 63110, USA
J Hepatol 43:434-41. 2005..We assessed serum AFP among patients with chronic hepatitis C and advanced fibrosis to establish predictors of AFP elevations and changes with antiviral therapy...
- Advancing patient care: integrating new dataTeresa L Wright
University of California-San Francisco, and VA Medical Center 111B, San Francisco, CA 94121, USA
Am J Gastroenterol 101:S32-9. 2006..A number of issues were identified, and statements concerning possible management strategies that could be applied were developed...